Latest Ratios: P/E Ratio -4.8x · EV/EBITDA N/A · ROE -30.2%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $1.6B | $1.9B | $1.2B | $1.5B | $2.0B | $3.0B | $2.9B | $2.6B | $2.7B | $1.6B |
| Enterprise Value | $1.7B | $1.5B | $1.9B | $1.2B | $1.5B | $1.9B | $3.0B | $2.9B | $1.8B | $2.1B | $1.1B |
| P/E Ratio → | -4.75 | — | 2.82 | — | — | — | — | — | — | — | — |
| P/S Ratio | 12.53 | 29.21 | 52.12 | 46.21 | 108.04 | — | — | 24.30 | 28.05 | 61.92 | 23.36 |
| P/B Ratio | 1.44 | 1.32 | 1.23 | 1.53 | 1.40 | 1.54 | 7.48 | 4.47 | 3.85 | 7.09 | 4.55 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 57.00 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 42.34 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 28.30 | 51.59 | 45.60 | 104.28 | — | — | 24.57 | 19.52 | 48.72 | 15.15 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 2.62 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 36.97 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.7% | 78.7% | 88.6% | 64.6% | 88.0% | — | — | 98.9% | 98.5% | -580.5% | -215.0% |
| Operating Margin | -873.9% | -873.9% | -1166.5% | -1459.5% | -2732.1% | — | — | -361.6% | -384.0% | -745.8% | -287.6% |
| Net Profit Margin | -764.0% | -764.0% | 1845.9% | -1312.6% | -1627.8% | — | — | -349.0% | -366.6% | -731.6% | -284.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -30.2% | 57.3% | -36.8% | -19.4% | 189.7% | -63.0% | -62.0% | -65.1% | -85.7% | -56.4% |
| ROA | -27.9% | -27.9% | 51.8% | -32.4% | -17.3% | 140.1% | -37.5% | -47.0% | -47.0% | -51.0% | -38.2% |
| ROIC | -26.6% | -26.6% | -27.6% | -31.9% | -26.1% | -36.3% | -48.0% | -115.1% | — | — | — |
| ROCE | -33.8% | -33.8% | -34.7% | -38.3% | -30.5% | -35.4% | -43.2% | -54.6% | -56.4% | -61.1% | -44.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.04 | 0.09 | 0.08 | 0.08 | 0.26 | 0.18 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.01 | -0.02 | -0.05 | -0.08 | -0.06 | 0.05 | -1.17 | -1.51 | -1.60 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -20.02 |
| Interest Coverage | — | — | — | — | — | — | -18.47 | — | — | — | — |
Net cash position: cash ($89M) exceeds total debt ($40M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.46 | 11.46 | 11.90 | 12.27 | 13.30 | 17.79 | 6.74 | 6.59 | 6.56 | 4.69 | 6.33 |
| Quick Ratio | 11.06 | 11.06 | 11.56 | 11.99 | 13.16 | 17.79 | 6.74 | 6.51 | 6.55 | 6.20 | 6.70 |
| Cash Ratio | 10.39 | 10.39 | 11.01 | 11.43 | 12.50 | 17.05 | 6.07 | 6.08 | 8.61 | 5.98 | 6.49 |
| Asset Turnover | — | 0.04 | 0.02 | 0.03 | 0.01 | — | — | 0.13 | 0.11 | 0.07 | 0.11 |
| Inventory Turnover | 0.35 | 0.35 | 0.15 | 0.50 | 0.20 | — | — | 0.18 | 1.61 | — | — |
| Days Sales Outstanding | — | 71.46 | 41.09 | 38.24 | 56.54 | — | — | 47.42 | 40.38 | 31.14 | 43.42 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 35.4% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 1.8% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 40.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 40.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $58M | $58M | $56M | $55M | $60M | $69M | $60M | $57M | $47M | $39M |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AGIO stock.
Agios Pharmaceuticals, Inc.'s current P/E ratio is -4.8x. The historical average is 2.8x.
Agios Pharmaceuticals, Inc.'s return on equity (ROE) is -30.2%. The historical average is -22.8%.
Based on historical data, Agios Pharmaceuticals, Inc. is trading at a P/E of -4.8x. Compare with industry peers and growth rates for a complete picture.
Agios Pharmaceuticals, Inc. has 78.7% gross margin and -873.9% operating margin.
Key Metrics
Top Statement Risk
Persistent operating losses and cash burn
Metrics are mathematically derived from official filings.
Cash-Plus-Pipeline Valuation Despite Losses
Based on reported figures, AGIO trades at a P/S of 12.42 and P/B of 1.43 because its P/E of -4.71 is meaningless, so the market appears to be pricing the pipeline rather than current earnings against roughly $54.0M of TTM revenue.
The negative P/E reflects a net loss so large relative to earnings that the multiple carries no analytical information, so valuation must be anchored to sales and book value instead. A P/S of 12.42 implies investors are paying a substantial premium on a revenue base still under $60M per quarter, which suggests they are capitalizing expected PYRUKYND growth and label expansion. The P/B of 1.43 sits modestly above book, but book value is itself eroding through accumulated losses, so investors should monitor whether the premium compresses as equity declines.
Gross Margin Strength Versus Operating Deficit
As reported in financial statements, AGIO's gross margin expanded from 64.2% in 2024Q2 to 95.4% in 2026Q3, yet the operating margin remained at -139.3% in the latest quarter, indicating gross profit is far too small to absorb the cost base.
The gross margin trajectory suggests the orphan-drug pricing model is structurally sound, since manufacturing costs appear low relative to realized price. However, operating margin volatility, moving from -2.5% in 2026Q2 to -139.3% in 2026Q3, indicates quarterly expense timing or revenue recognition may be distorting the picture and should be treated cautiously. Net margin of -117.4% in the latest quarter suggests operating leverage has not yet emerged, and investors should watch whether operating expenses stabilize relative to revenue.
Minimal Debt Limits Solvency Pressure
According to recent SEC filings, AGIO's debt-to-equity ratio fell from 0.10 to 0.03 over the period, suggesting leverage is not the primary balance sheet concern, though interest coverage cannot be assessed from the data provided.
A debt-to-equity decline from 0.10 in 2024Q2 to 0.03 indicates the company has largely deleveraged, which may reduce refinancing and covenant risk. The absence of a reported interest coverage ratio means debt service cannot be evaluated directly, and no comfort should be inferred from that gap. The more relevant risk appears to be equity erosion, as negative ROE of -6.5% in the latest quarter continues to consume book value.
Current Ratio Masks Thin Cash Cushion
Based on reported figures, AGIO's current ratio of 9.69 and quick ratio of 9.21 in 2026Q3 appear strong, but cash of roughly $128.5M against quarterly operating burn well above that level suggests a limited runway.
Current and quick ratios near 9 to 10 are high, but they are dominated by liquid assets being consumed by operations rather than representing durable financial strength. Because quick and current ratios are nearly identical, inventory appears immaterial to liquidity, which is consistent with a small-molecule product where working capital sits largely in receivables and cash. Under severe stress, the relevant question is whether cash reserves can fund operations through the next pipeline catalyst, which warrants further investigation given the reported cash discrepancy flagged in prior analysis.
Working Capital Cycle Stretched by Inventory
As reported in financial statements, AGIO's inventory days of roughly 1,239 and cash conversion cycle of 616 days in 2026Q3 suggest significant working capital tied up in slow-moving stock relative to sales.
Inventory days at extreme levels may indicate a very small revenue base relative to stocked inventory or timing effects from production batches, which could reflect a mismatch between manufacturing volume and patient demand. DPO of 661 days is unusually high and implies heavy reliance on supplier credit, which may be sustainable but warrants monitoring. Asset turnover of 0.05 suggests the asset base is heavily underutilized relative to revenue, consistent with a company still building commercial scale.
Ratio Optics Versus Cash Reality
Based on reported figures, the 9.69 current ratio and 0.03 debt-to-equity may understate risk, since operating cash flow has been negative in every quarter shown and stock-based compensation of roughly $11M to $17M per quarter is added back in reported cash flow.
Strong headline liquidity and low leverage can be misleading for a burning biotech, because balance sheet ratios capture a snapshot rather than the rate of cash consumption. Adding back stock-based compensation flatters operating cash flow, and treating it as a real economic cost would likely deepen the apparent burn. Investors should therefore weight free cash flow margin, which ranged from -5.8% to -130.8% across recent quarters, more heavily than static balance sheet ratios when judging funding needs.